Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Intravenous fat emulsion Clear all

Conditions: Obesity
Interventions: Intralipid, 20% Intravenous Emulsion, Placebos; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Chapel Hill, North Carolina

Conditions: Parenteral Nutrition-Associated Liver Disease
Interventions: Intravenous fat emulsion, Restriction of intravenous fat emulsion to 1 gm/kg/d; Other
Lead sponsor: Yale University; Other
Eligibility: 12 Hours to 48 Hours
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cholestasis
Interventions: Omegaven; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 1 Month to 18 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Cholestasis, Parenteral Nutrition
Interventions: Omegaven, Intralipid; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Up to 3 Months
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Liver Injury
Interventions: Omegaven™, Historical Controls; Drug · Other
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: Up to 21 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cholestasis, Growth Failure
Interventions: SMOFlipid; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 14 Days to 1 Year
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cholestasis
Interventions: Intralipid; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 1 Minute to 5 Days
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Los Angeles, California • St Louis, Missouri

Conditions: Breast Abscess
Interventions: Standard of care breast abscess drainage, Methylene Blue, Lipid Emulsion, Insertion of optical fiber, Laser illumination, Photodynamic therapy; Procedure · Drug · Device
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Total Parenteral Nutrition-induced Cholestasis
Interventions: Omegaven®; Drug
Lead sponsor: Jeffrey Rudolph; Other
Eligibility: 2 Months to 10 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Malnutrition, Child, Malnutrition, Essential Fatty Acid Deficiency (EFAD), Parenteral Nutrition Associated Cholestasis
Interventions: SMOFlipid® (lipid injectable emulsion); Drug
Lead sponsor: Fresenius Kabi; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 3 more

Conditions: Hypertension, Diabetes
Interventions: Salsalate, Carvedilol, Placebo, Intralipid 20%; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Abscess
Interventions: Methylene Blue, Lipid Emulsion, Insertion of optical fiber, Laser Illumination (pre-defined dose), Optical Spectroscopy Measurement, Laser Illumination (patient-specific dose), Standard of care abscess drainage; Drug · Device · Procedure
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 2
States / cities: Rochester, New York

Conditions: Endothelial Dysfunction, Hypertension
Interventions: Intralipid 20% @ 20cc/hour, Intralipid 20%@ 40cc/hour, Normal Saline, 32-gram oral fat load, 64-gram oral fat load; Drug · Dietary Supplement
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hospitalized Neonates and Infants, Expected to Require Parenteral Nutrition for 28 Days
Interventions: Smoflipid 20% (investigational lipid for parenteral nutrition), Intralipid® 20%; Drug
Lead sponsor: Fresenius Kabi; Industry
Eligibility: 0 Weeks and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 13
States / cities: Palo Alto, California • San Diego, California • New Haven, Connecticut + 8 more

Conditions: Cholestasis
Interventions: Intralipid 20% I.V. Fat Emulsion; Drug
Lead sponsor: University of Michigan; Other
Eligibility: Up to 1 Year
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 5
States / cities: Aurora, Colorado • Gainesville, Florida • Ann Arbor, Michigan + 2 more

Conditions: Total Parenteral Nutrition-induced Cholestasis
Interventions: Omegaven, Omegaven; Dietary Supplement · Drug
Lead sponsor: Pediatrix; Other
Eligibility: 14 Days to 2 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetes Mellitus, Type 2, Insulin Resistance, Insulin Sensitivity
Interventions: Intralipid, 20% Intravenous Emulsion; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 44 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Brain Tumor, Recurrent
Interventions: Photofrin (porfimer sodium) & photodynamic therapy.; Drug
Lead sponsor: Harry T Whelan, MD; Other
Eligibility: 6 Months to 18 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Wauwatosa, Wisconsin

Conditions: Hypertriglyceridemia, Hyperglycemia
Interventions: Intravenous Fat Emulsions; Drug
Lead sponsor: OSF Healthcare System; Other
Eligibility: 1 Day to 2 Days
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Peoria, Illinois

Conditions: Cholestasis of Parenteral Nutrition
Interventions: Smoflipid 20% Lipid Emulsion for Injection, Intralipid, 20% Intravenous Emulsion; Drug
Lead sponsor: Indiana University; Other
Eligibility: Not listed
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Neoplasms
Interventions: MST-997; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: New York, New York • Cleveland, Ohio • Nashville, Tennessee

Conditions: Type 2 Diabetes, Hypertension
Interventions: Rosiglitazone, Normal saline 0.9%, Intralipid 20%; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Malnutrition, Child
Interventions: Smoflipid, Intralipid, 20%; Drug
Lead sponsor: Fresenius Kabi; Industry
Eligibility: 3 Months to 16 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Traumatic Brain Injury
Interventions: Progesterone, Placebo; Drug
Lead sponsor: David Wright; Other
Eligibility: 18 Years and older
Enrollment: 882 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 36
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tuscon, Arizona + 26 more

Search by objective public record fields.

Investigating Whether Acute Elevation of Fatty Acid Levels Alters Cerebral Glucose Transport and Metabolism

Low Dose Parenteral Fat for Prevention of Parenteral Nutrition Associated Cholestasis in Preterm Neonates

Compassionate Use of Omegaven to Reverse Parenteral Nutrition Induced Cholestasis

Cholestasis Prevention: Efficacy of IV Fish Oil

Omegaven Treatment of Parenteral Nutrition (PN) Induced Liver Injury

SMOF Lipid for Children With Parenteral Nutrition Induced Liver Injury

Low Dose Fat for the Prevention of Liver Disease in Babies With Gastrointestinal Disorders

A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses

Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Associated Hepatic Injury

Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients

Free Fatty Acids-Induced Hypertension in Obese Subjects (Aim #2)

Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses

FFA-Induced Hypertension and Endothelial Dysfunction

Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants

Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD

Intravenous Fat Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Infants

Low Dose Fat-Induced Insulin Resistance

Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors

Intravenous Fat Emulsions and Premature Infants

Comparison of Smoflipid to Soy-based Lipid Reduction for Cholestasis Prevention in Surgical Neonates

Study Evaluating MST-997 in Advanced Malignant Solid Tumors

Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes

Safety and Efficacy Study to Compare Smoflipid and Intralipid 20% in Pediatric Patients of 3 Months to 16 Years of Age

Progesterone for the Treatment of Traumatic Brain Injury III